In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Chimerix, Inc.. Trade Record

NASDAQ:CMRX Chimerix, Inc. stock gains 6.15% Exit Jan 11, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart CMRX Dec 21, 2017, priceSeries
About Chimerix, Inc.

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Trade Information
Trade Type
LONG
ReliabilityScore™
99.60
Entry Date
Dec 21, 2017
Entry Price
4.44
Sell Date
Jan 11, 2018
Sell Price
4.71
Net Gain
6.15%
Hold Time
13 Trading Days